An interventional study of Multisegment Transcutaneous Spinal Cord Stimulation (scTS) and Activity-Based Training (ABT) in Spinal Cord Injuries (Complete and Incomplete), sponsored by Dr. Gabriel Zeilig. Not yet recruiting at 1 site in Israel. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-11-16.
Sponsored by Dr. Gabriel Zeilig · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 11 studies in Spinal Cord Injuries with a site in Israel — 5 open to participants now, 5 under way, none of them phase 3. Spinal Cord Injuries · Israel.
Among the 11 studies in Spinal Cord Injuries with a site in Israel, this one is the only one that started in 2027, is one of 6 with no phase, and was the 11th registered.
2,028 studies on the registry are indexed under Spinal Cord Injuries; 538 are open to participants now.
Browse Spinal Cord Injuries studies →5 of the 11 studies in Spinal Cord Injuries with a site in Israel are open now. Recruiting first, the newest first:
Motion Informatics LTD · Sites in Israel
Ages 18+
Loewenstein Hospital · Sites in Israel
Ages 18+
St George's, University of London · Sites in Israel, Austria, Belgium and 9 more countries
Ages 16+
Loewenstein Hospital · Sites in Israel
Ages 18+
A study can be open while its sites in Israel have not opened yet or have stopped. Only those recruiting at a site in Israel →
Of the 375 Spinal Cord Injuries studies recruiting now, 166 (44%) set no upper age limit and 158 (42%) stop at 75 or younger; 41 take children under 18; 52 take healthy volunteers.
This study: 18 Years to 65 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
11 studies; the count open now beside each. This study's row is marked.
First in 2003; this study’s year is marked. 1 started in 2027.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 10 is below the median of 24 across 1,634 interventional studies indexed under Spinal Cord Injuries.
Median enrollment 60 across the 9 interventional studies, 90 across the 2 observational. Of the 1 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
4 of 11 have an industry lead sponsor. The 9 most frequent:
Dr. Gabriel Zeilig is the lead sponsor of 2 studies on the registry; 1 is open to participants now.
Dr. Gabriel Zeilig has 1 study filed under Spinal Cord Injuries — fewer than ten, so there is no comparison to draw.
2 of the studies in Spinal Cord Injuries with a site in Israel that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07404761Motion Informatics LTDSafety and Effectiveness of Spatial StimelMD (SSMD) in Subjects With Upper Limb Neuromotor Impairments | 2026-12-30 |
| NCT05484557Loewenstein HospitalPrevention of Thromboembolism Using Apixaban vs Enoxaparin Following Spinal Cord Injury | 2027-08 |
Add all 2 to your calendar (.ics) → With an account.
Among the 11 studies in Spinal Cord Injuries with a site in Israel, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study will examine the safety, feasibility, and potential benefits of transcutaneous spinal cord stimulation (scTS) combined with activity-based training in people with spinal cord injury.
The study will include 10 adults with chronic, incomplete spinal cord injury. Electrical stimulation will be delivered through electrodes placed on the skin over different regions of the spinal cord, while participants perform exercises involving the arms, hands, trunk, and legs.
Participants will undergo initial assessments, individualized stimulation mapping, and 80 training sessions, followed by final assessments. Researchers will evaluate changes in motor function, muscle activity, psychological well-being, autonomic function, and quality of life. Safety and tolerability will also be monitored throughout the study.
This prospective, single-arm, within-subject exploratory study will enroll 10 adults aged 18-65 years with chronic incomplete cervical or thoracic spinal cord injury.
The study includes four phases: (1) baseline assessments over approximately two months; (2) stimulation mapping and optimization over approximately 0.5-1 month to identify individualized stimulation parameters; (3) 80 sessions of multisegment transcutaneous spinal cord stimulation combined with activity-based training, delivered 3-5 days per week over approximately 4-7 months; and (4) follow-up assessments.
The intervention targets upper and lower extremity function, trunk control, standing, and stepping. Motor performance will be assessed primarily using the Neuromuscular Recovery Scale (NRS). Additional assessments will examine muscle activation using electromyography (EMG), psychological symptoms, autonomic function, neurological status, spasticity, functional independence, and quality of life.
Intermediate assessments will be conducted during the intervention, including after 40 training sessions. Safety, adverse events, and feasibility will be evaluated throughout the study.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Participants will receive individualized multisegment transcutaneous spinal cord stimulation (scTS) combined with activity-based training targeting upper and lower extremity function, trunk control, standing, and stepping. The intervention will consist of 80 training sessions, delivered 3-5 days per week over approximately 4-7 months, with sessions lasting up to 2 hours.
Device: Multisegment Transcutaneous Spinal Cord Stimulation (scTS) · Other: Activity-Based Training (ABT)
Non-invasive electrical stimulation delivered through surface electrodes placed over multiple spinal levels using the NeoStim-5 system. Stimulation sites and parameters will be individually optimized to facilitate motor activation of the upper extremities, trunk, and lower extremities during activity-based training.
Individualized, task-specific rehabilitation training targeting voluntary control of the hands, arms, trunk, and legs, including seated activities, standing, and stepping. Training will be provided by rehabilitation staff and combined with transcutaneous spinal cord stimulation.
Motor Function (NRS)
Changes in motor performance assessed using the Neuromuscular Recovery Scale (NRS), which evaluates movement quality and the level of assistance required during upper extremity, trunk, standing, and stepping tasks. Changes in individual task ratings will be assessed across study time points.
Time frame: Baseline, after 40 training sessions, and after 80 training sessions (approximately 4-7 months of training).
Safety
Incidence of adverse events and equipment-related complications during the study. Adverse events will be categorized by severity, relatedness to study procedures, and expectedness.
Time frame: From enrollment through the final study assessment (approximately 7-10 months per participant).
Change in Surface EMG Amplitude During Functional Motor Tasks
Changes in surface electromyography (EMG) signal amplitude during functional motor tasks involving upper extremity, trunk, and lower extremity muscles.
Time frame: Baseline, after 40 training sessions, and after 80 training sessions (approximately 4-7 months of training).
Depression (PHQ-9)
Changes in depressive symptoms measured using the 9-item Patient Health Questionnaire (PHQ-9). Total scores range from 0 to 27, with higher scores indicating greater depressive symptom severity.
Time frame: Baseline, after 40 training sessions, and after 80 training sessions (approximately 4-7 months of training).
Anxiety (GAD-7)
Changes in anxiety symptoms measured using the 7-item Generalized Anxiety Disorder scale (GAD-7). Total scores range from 0 to 21, with higher scores indicating greater anxiety symptom severity.
Time frame: Baseline, after 40 training sessions, and after 80 training sessions (approximately 4-7 months of training).
PTSD (PCL-5)
Changes in self-reported post-traumatic stress symptoms measured using the PTSD Checklist for DSM-5 (PCL-5). Total scores range from 0 to 80, with higher scores indicating greater symptom severity.
Time frame: Baseline, after 40 training sessions, and after 80 training sessions (approximately 4-7 months of training)
PTSD (CAPS-5)
Changes in clinician-rated post-traumatic stress symptom severity measured using the CAPS-5. The total severity score ranges from 0 to 80, with higher scores indicating greater symptom severity.
Time frame: Baseline, after 40 training sessions, and after 80 training sessions (approximately 4-7 months of training).
Change in ISNCSCI Total Motor Score
Change in motor function assessed using the International Standards for Neurological Classification of Spinal Cord Injury (ISNCSCI). The total motor score ranges from 0 to 100, with higher scores indicating better motor function.
Time frame: Baseline and post-training assessment (after 80 training sessions; approximately 4-7 months of training)
Change in Modified Ashworth Scale (MAS) Score
Change in muscle spasticity assessed by a clinician using the Modified Ashworth Scale, which grades resistance to passive movement.
Time frame: Baseline and post-training assessment (after 80 training sessions; approximately 4-7 months of training)
Change in Spinal Cord Injury Spasticity Evaluation Tool (SCI-SET) Score
Change in the self-reported impact of spasticity on daily activities, assessed using the SCI-SET questionnaire covering the preceding seven days.
Time frame: Baseline and post-training assessment (after 80 training sessions; approximately 4-7 months of training)
Change in Autonomic Dysfunction Following Spinal Cord Injury (ADFSCI) Questionnaire Score
Change in frequency and severity of symptoms associated with blood pressure instability, assessed using the 24-item ADFSCI questionnaire.
Time frame: Baseline and post-training assessment (after 80 training sessions; approximately 4-7 months of training)
Change in Modified Functional Reach Test Distance
Change in maximum forward reaching distance while seated, measured using the Modified Functional Reach Test
Time frame: Baseline and post-training assessment (after 80 training sessions; approximately 4-7 months of training)
Change in Activity-Based Balance Level (ABLE) Sitting Subscale Score
Change in sitting balance assessed using the seven items of the ABLE sitting subscale, with a maximum score of 32.
Time frame: Baseline and post-training assessment (after 80 training sessions; approximately 4-7 months of training)
Plan to share: No
No publications or documents are linked to this record.
Start is estimated for Jan 2027; primary completion for Jan 2029, 24 months later.
Of 790 non-industry interventional studies with no phase under Spinal Cord Injuries, half reached primary completion within 37 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 65. This study's planned 24 months is below that.
Counting every sponsor, half of 839 studies reached it within 36 months; a quarter within 17 and three quarters within 64.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is not yet recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Dr. Gabriel Zeilig